GSK Says Amgen Patent Decision Will 'Devastate' Innovation
Pharmaceutical giant GlaxoSmithKline PLC on Wednesday threw its support behind Amgen in a patent dispute over the cholesterol medication Repatha, telling the Federal Circuit that a panel's decision earlier this year...To view the full article, register now.
Already a subscriber? Click here to view full article